[HTML][HTML] Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC
A Vergnenegre, B Massuti, F de Marinis… - Journal of Thoracic …, 2016 - Elsevier
Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
[HTML][HTML] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
MS Holleman, MJ Al, R Zaim, HJM Groen… - The European Journal of …, 2020 - Springer
Objectives To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and
osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal …
osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal …
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell …
OBJECTIVE: To compare the effectiveness and cost-effectiveness of erlotinib versus gefitinib
as first-line treatment of epidermal growth factor receptor-activating mutation-positive non …
as first-line treatment of epidermal growth factor receptor-activating mutation-positive non …
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis
PS Bajaj, DL Veenstra, HP Goertz… - Journal of medical …, 2014 - Taylor & Francis
Objectives: A recent phase III trial showed that patients with advanced non-small cell lung
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …
OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non …
F Wen, H Zheng, P Zhang, D Hutton, Q Li - BMJ open, 2018 - bmjopen.bmj.com
Objectives Erlotinib, the first generation of epidermoid growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI), has been recommended as an essential treatment in patients with non …
inhibitor (EGFR-TKI), has been recommended as an essential treatment in patients with non …
[HTML][HTML] A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous …
S Wang, L Peng, J Li, X Zeng, L Ouyang, C Tan, Q Lu - PLoS One, 2013 - journals.plos.org
Introduction Lung cancer, the most prevalent malignant cancer in the world, remains a
serious threat to public health. Recently, a large number of studies have shown that an …
serious threat to public health. Recently, a large number of studies have shown that an …
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
D Isla, J De Castro, O Juan, S Grau… - ClinicoEconomics …, 2016 - Taylor & Francis
Objectives Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …
[HTML][HTML] Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non …
J Ting, PDT Ho, P Xiang, A Sugay, M Abdel-Sattar… - Value in Health, 2015 - Elsevier
Objectives To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or
afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial …
afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial …
[HTML][HTML] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation …
M Kimura, F Yasue, E Usami… - Molecular and …, 2018 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non …
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients …
K Schremser, WH Rogowski, S Adler-Reichel… - …, 2015 - Springer
Background Lung cancer is among the top causes of cancer-related deaths. Epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free …
growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free …